Hims, Weight Loss

Hims & Hers shares drop on doubts over weight-loss business forecast
Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's lofty sales forecast in the face of looming restrictions on compounded weight-loss drugs.
Novo Nordisk Stock Rises on Weight-Loss Retreat by Hims & Hers
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood about 17% lower at under $42.
These Drugs Could Offset the Side Effects of Weight Loss
Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
Hims & Hers warns it may stop selling compounded weight-loss drugs
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.
Hims & Hers shares tumble after company misses on margin, says may stop selling some weight loss drugs
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended trading.
Hims Stock Drops on Uncertainty About Weight-Loss Business
Hims & Hers Health Inc. shares lost as much as a fifth of their value in after-market trading Monday after the company said that it will soon stop selling some compound weight-loss drugs.
Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop making copies.
Weight-loss drugs aren’t just slimming waists. They’re shifting the economy.
Ozempic, Mounjaro and Wegovy may not be the lightbulb, jet airplane or internet, but their impact is expected to be so ...
Yearslong shortage of popular weight-loss and diabetes drugs resolved, FDA says
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...
Patients struggle with lack of consistent coverage for popular weight-loss drugs
Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...
Novo’s Weight Loss Drugs Removed from FDA Shortage List
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...
ConsumerAffairs12d
Ozempic vs. Wegovy: Which is best for weight loss?
Few things have stirred up as much commotion in either the weight loss or pharmaceutical world as Ozempic and Wegovy. There's a good reason for that — these drugs have proven to be highly ...
Yearslong shortage of popular weight-loss and diabetes drugs is resolved, FDA says
Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...
Ozempic, Wegovy Linked To Potential Vision Loss
Patients on semaglutide ( Ozempic, Wegovy) had a 32% increased relative risk of developing nonarteritic anterior ischemic ...
In China you can get Ozempic and Wegovy within the hour for just $100 a month
Delivery apps are allowing Chinese citizens to get their hands on the popular weight-loss and diabetes drugs at the touch of a button.